Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Top Cited Papers
- 17 July 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (3), 242-251
- https://doi.org/10.1056/nejmoa0707894
Abstract
Few options for transplantation currently exist for patients highly sensitized to HLA. This exploratory, open-label, phase 1–2, single-center study examined whether intravenous immune globulin plus rituximab could reduce anti-HLA antibody levels and improve transplantation rates.This publication has 26 references indexed in Scilit:
- Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and RituximabAmerican Journal of Transplantation, 2008
- Rituximab Therapy for Acute Humoral Rejection After Kidney TransplantationTransplantation, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Current approaches to treatment of antibody‐mediated rejectionPediatric Transplantation, 2005
- Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodiesTransplant International, 2004
- INTRAVENOUS IMMUNOGLOBULIN SUPPRESSION OF HLA ALLOANTIBODY IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES AND TRANSPLANTATION WITH A HISTOINCOMPATIBLE ORGANTransplantation, 1994
- Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipientsJAMA, 1993
- THE QUALITY OF LIFE IN RENAL TRANSPLANTATION—A PROSPECTIVE STUDYTransplantation, 1992
- THE FLOW CYTOMETRIC CROSSMATCHTransplantation, 1989
- The Quality of Life of Patients with End-Stage Renal DiseaseNew England Journal of Medicine, 1985